1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Blood Transfusion Diagnostics Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Blood Transfusion Diagnostics Market Analysis and Forecast, 2017–2031
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product/Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Blood Transfusion Diagnostics Market Analysis and Forecast, by Product Type
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Product Type, 2017–2031
        6.3.1. Instruments
        6.3.2. Kits & Reagents
    6.4. Market Attractiveness Analysis, by Product Type
7. Global Blood Transfusion Diagnostics Market Analysis and Forecast, by Application
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Application, 2017–2031
        7.3.1. Blood Grouping
        7.3.2. Disease Screening
            7.3.2.1. Molecular Disease Screening
            7.3.2.2. Serological Disease Screening
    7.4. Market Attractiveness Analysis, by Application
8. Global Blood Transfusion Diagnostics Market Analysis and Forecast, by End-user
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by End-user, 2017–2031
        8.3.1. Hospitals
        8.3.2. Diagnostics Laboratories
        8.3.3. Blood Banks
        8.3.4. Plasma Fractionation Companies
        8.3.5. Others
    8.4. Market Attractiveness Analysis, by Application
9. Global Blood Transfusion Diagnostics Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region, 2017–2031
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region
10. North America Blood Transfusion Diagnostics Market Analysis and Forecast
    10.1. Introduction
    10.2. Key Findings
    10.3. Market Value Forecast, by Product Type, 2017–2031
        10.3.1. Instruments
        10.3.2. Kits & Reagents
    10.4. Market Value Forecast, by Application, 2017–2031
        10.4.1. Blood Grouping
        10.4.2. Disease Screening
            10.4.2.1. Molecular Disease Screening
            10.4.2.2. Serological Disease Screening
    10.5. Market Value Forecast, by End-user, 2017–2031
        10.5.1. Hospitals
        10.5.2. Diagnostics Laboratories
        10.5.3. Blood Banks
        10.5.4. Plasma Fractionation Companies
        10.5.5. Others
    10.6. Market Value Forecast, by Country, 2017–2031
        10.6.1. U.S.
        10.6.2. Canada
    10.7. Market Attractiveness Analysis
        10.7.1. By Product Type
        10.7.2. By Application
        10.7.3. By End-user
        10.7.4. By Country
11. Europe Blood Transfusion Diagnostics Market Analysis and Forecast
    11.1. Introduction
    11.2. Key Findings
    11.3. Market Value Forecast, by Product Type, 2017–2031
        11.3.1. Instruments
        11.3.2. Kits & Reagents
    11.4. Market Value Forecast, by Application, 2017–2031
        11.4.1. Blood Grouping
        11.4.2. Disease Screening
            11.4.2.1. Molecular Disease Screening
            11.4.2.2. Serological Disease Screening
    11.5. Market Value Forecast, by End-user, 2017–2031
        11.5.1. Hospitals
        11.5.2. Diagnostics Laboratories
        11.5.3. Blood Banks
        11.5.4. Plasma Fractionation Companies
        11.5.5. Others
    11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.6.1. Germany
        11.6.2. U.K.
        11.6.3. France
        11.6.4. Italy
        11.6.5. Spain
        11.6.6. Rest of Europe
    11.7. Market Attractiveness Analysis
        11.7.1. By Product Type
        11.7.2. By Application
        11.7.3. By End-user
        11.7.4. By Country/Sub-region
12. Asia Pacific Blood Transfusion Diagnostics Market Analysis and Forecast
    12.1. Introduction
    12.2. Key Findings
    12.3. Market Value Forecast, by Product Type, 2017–2031
        12.3.1. Instruments
        12.3.2. Kits & Reagents
    12.4. Market Value Forecast, by Application, 2017–2031
        12.4.1. Blood Grouping
        12.4.2. Disease Screening
            12.4.2.1. Molecular Disease Screening
            12.4.2.2. Serological Disease Screening
    12.5. Market Value Forecast, by End-user, 2017–2031
        12.5.1. Hospitals
        12.5.2. Diagnostics Laboratories
        12.5.3. Blood Banks
        12.5.4. Plasma Fractionation Companies
        12.5.5. Others
    12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.6.1. China
        12.6.2. Japan
        12.6.3. India
        12.6.4. Australia & New Zealand
        12.6.5. Rest of Asia Pacific
    12.7. Market Attractiveness Analysis
        12.7.1. By Product Type
        12.7.2. By Application
        12.7.3. By End-user
        12.7.4. By Country/Sub-region
13. Latin America Blood Transfusion Diagnostics Market Analysis and Forecast
    13.1. Introduction
    13.2. Key Findings
    13.3. Market Value Forecast, by Product Type, 2017–2031
        13.3.1. Instruments
        13.3.2. Kits & Reagents
    13.4. Market Value Forecast, by Application, 2017–2031
        13.4.1. Blood Grouping
        13.4.2. Disease Screening
            13.4.2.1. Molecular Disease Screening
            13.4.2.2. Serological Disease Screening
    13.5. Market Value Forecast, by End-user, 2017–2031
        13.5.1. Hospitals
        13.5.2. Diagnostics Laboratories
        13.5.3. Blood Banks
        13.5.4. Plasma Fractionation Companies
        13.5.5. Others
    13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.6.1. Brazil
        13.6.2. Mexico
        13.6.3. Rest of Latin America
    13.7. Market Attractiveness Analysis
        13.7.1. By Product Type
        13.7.2. By Application
        13.7.3. By End-user
        13.7.4. By Country/Sub-region
14. Middle East & Africa Blood Transfusion Diagnostics Market Analysis and Forecast
    14.1. Introduction
    14.2. Key Findings
    14.3. Market Value Forecast, by Product Type, 2017–2031
        14.3.1. Instruments
        14.3.2. Kits & Reagents
    14.4. Market Value Forecast, by Application, 2017–2031
        14.4.1. Blood Grouping
        14.4.2. Disease Screening
            14.4.2.1. Molecular Disease Screening
            14.4.2.2. Serological Disease Screening
    14.5. Market Value Forecast, by End-user, 2017–2031
        14.5.1. Hospitals
        14.5.2. Diagnostics Laboratories
        14.5.3. Blood Banks
        14.5.4. Plasma Fractionation Companies
        14.5.5. Others
    14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.6.1. GCC Countries
        14.6.2. South Africa
        14.6.3. Rest of Middle East & Africa
    14.7. Market Attractiveness Analysis
        14.7.1. By Product Type
        14.7.2. By Application
        14.7.3. By End-user
        14.7.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player – Competitive Matrix (by Tier and Size of Companies)
    15.2. Market Share Analysis, by Company (2022)
    15.3. Company Profiles
        15.3.1. Grifols, S.A.
            15.3.1.1. Company Overview
            15.3.1.2. Product Portfolio
            15.3.1.3. SWOT Analysis
            15.3.1.4. Financial Overview
            15.3.1.5. Strategic Overview
        15.3.2. Werfen
            15.3.2.1. Company Overview
            15.3.2.2. Product Portfolio
            15.3.2.3. SWOT Analysis
            15.3.2.4. Financial Overview
            15.3.2.5. Strategic Overview
        15.3.3. Ortho Clinical Diagnostics
            15.3.3.1. Company Overview
            15.3.3.2. Product Portfolio
            15.3.3.3. SWOT Analysis
            15.3.3.4. Financial Overview
            15.3.3.5. Strategic Overview
        15.3.4. Abbott
            15.3.4.1. Company Overview
            15.3.4.2. Product Portfolio
            15.3.4.3. SWOT Analysis
            15.3.4.4. Financial Overview
            15.3.4.5. Strategic Overview
        15.3.5. Bio-Rad Laboratories, Inc.
            15.3.5.1. Company Overview
            15.3.5.2. Product Portfolio
            15.3.5.3. SWOT Analysis
            15.3.5.4. Financial Overview
            15.3.5.5. Strategic Overview
        15.3.6. F. Hoffmann-La Roche AG
            15.3.6.1. Company Overview
            15.3.6.2. Product Portfolio
            15.3.6.3. SWOT Analysis
            15.3.6.4. Financial Overview
            15.3.6.5. Strategic Overview
        15.3.7. Alive Dx
            15.3.7.1. Company Overview
            15.3.7.2. Product Portfolio
            15.3.7.3. SWOT Analysis
            15.3.7.4. Financial Overview
            15.3.7.5. Strategic Overview
        15.3.8. BAG Health Care GmbH
            15.3.8.1. Company Overview
            15.3.8.2. Product Portfolio
            15.3.8.3. SWOT Analysis
            15.3.8.4. Financial Overview
            15.3.8.5. Strategic Overview
        15.3.9. DiaSorin S.p.A.
            15.3.9.1. Company Overview
            15.3.9.2. Product Portfolio
            15.3.9.3. SWOT Analysis
            15.3.9.4. Financial Overview
            15.3.9.5. Strategic Overview
        15.3.10. Hologic, Inc.
            15.3.10.1. Company Overview
            15.3.10.2. Product Portfolio
            15.3.10.3. SWOT Analysis
            15.3.10.4. Financial Overview
            15.3.10.5. Strategic Overview
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


 
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			